I am a breastfeeding mother and i want to know if it is safe to use UCB 492? Is UCB 492 safe for nursing mother and child? Does UCB 492 extracts into breast milk? Does UCB 492 has any long term or short term side effects on infants? Can UCB 492 influence milk supply or can UCB 492 decrease milk supply in lactating mothers?
- DrLact safety Score for UCB 492 is 1 out of 8 which is considered Safe as per our analyses.
- A safety Score of 1 indicates that usage of UCB 492 is mostly safe during lactation for breastfed baby.
- Our study of different scientific research also indicates that UCB 492 does not cause any serious side effects in breastfeeding mothers.
- Most of scientific studies and research papers declaring usage of UCB 492 safe in breastfeeding are based on normal dosage and may not hold true for higher dosage.
- Score calculated using the DrLact safety Version 1.2 model, this score ranges from 0 to 8 and measures overall safety of drug in lactation. Scores are primarily calculated using publicly available case studies, research papers, other scientific journals and publically available data.
First-generation antihistamine, piperazine derived drug with mild sedative effect. It is metabolized into Cetirizine which is compatible with breastfeeding. (See info at specific item) At last update no relevant information concerning breastfeeding were found. Since it has been shown to be well tolerated by young infants for itching relief and because it is metabolized into Cetirizine, we would assume that there is a low risk for breastfeeding in short-term treatments. Follow-up for sedation or irritability in the infant and feeding ability of the infant. Bed-sharing is not recommended for mothers who are taking this medication.
Small occasional doses of UCB 492 would not be expected to cause any adverse effects in breastfed infants. Larger doses or more prolonged use may cause drowsiness and other effects in the infant or decrease the milk supply, particularly in combination with a sympathomimetic such as pseudoephedrine or before lactation is well established. Other agents are preferred, especially while nursing a newborn or preterm infant.
In one telephone follow-up study, mothers reported irritability and colicky symptoms 10% of infants exposed to various antihistamines and drowsiness was reported in 1.6% of infants. None of the reactions required medical attention. All adverse reactions in breastfed infants reported in France between January 1985 and June 2011 were compiled by a French pharmacovigilance center. Of 174 reports, UCB 492 was reported to cause adverse reactions in 8 infants and to be one of the drugs most often suspected in serious adverse reactions, primarily sedation.
Antihistamines in relatively high doses given by injection can decrease basal serum prolactin in nonlactating women and in early postpartum women. However, suckling-induced prolactin secretion is not affected by antihistamine pretreatment of postpartum mothers. Whether lower oral doses of antihistamines have the same effect on serum prolactin or whether the effects on prolactin have any consequences on breastfeeding success have not been studied. The prolactin level in a mother with established lactation may not affect her ability to breastfeed.
: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. We do not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.